Fed. Circ. Iffy On Alvogen's Bid To Unblock Generic Opioid
An attorney for Alvogen met some stiff resistance on Tuesday from a Federal Circuit panel that grilled him over the company's bid to kill claims in two BioDelivery Sciences patents on...To view the full article, register now.
Already a subscriber? Click here to view full article